Non Small Cell Lung Cancer Clinical Trials in Sarasota, Florida

6 studies are recruiting for non small cell lung cancer in Sarasota, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists & Research Institute - Sarasota Cattlemen, Sarasota, Florida

   Locations

   4 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

2. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

   A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists & Research Institute - Sarasota, Sarasota, Florida

   Locations

   3 in total

   Run by

   Blueprint Medicines Corporation

   See if you can join NCT07629960 on ClinicalTrials.gov

3. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

   This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Florida Cancer Specialists, Sarasota, Florida

   Locations

   440 in total

   Run by

   Pfizer

   See if you can join NCT07222566 on ClinicalTrials.gov

4. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

   This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists - Sarasota, Sarasota, Florida

   Locations

   10 in total

   Run by

   Compass Therapeutics

   See if you can join NCT06150664 on ClinicalTrials.gov

5. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

   This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists, Sarasota, Florida

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07503808 on ClinicalTrials.gov

6. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

   A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dren Investigational Site, Sarasota, Florida

   Locations

   10 in total

   Run by

   Dren Bio

   See if you can join NCT06999187 on ClinicalTrials.gov